Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Ph 3 Trial of ANKTIVA and PD-1 Checkpoint Inhibitor Combination in NSCLC

February 4, 2025

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals

February 4, 2025

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

February 4, 2025

Orion and Invenra to develop innovative bispecific antibody cancer therapeutics

February 4, 2025

AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology

January 28, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

January 21, 2025

Simnova and Orna Expand Strategic Partnership to Include BCMA-Targeted RNA Therapeutics

January 21, 2025

ArsenalBio and BMS Achieve Milestone for AB-4000 Series to Advance Next-Gen T Cell Therapies for Solid Tumors

January 21, 2025

A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Precision Cell Therapies Using Proprietary Tmod Technology Platform

January 21, 2025

BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy

January 21, 2025

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

January 21, 2025

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

January 21, 2025

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology

January 15, 2025

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

January 15, 2025

Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program

January 15, 2025

Predictive Oncology Announces Agreement to be Acquired by Renovaro

January 15, 2025

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for EGFR/HER3 ADC

January 15, 2025

BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors

January 15, 2025

Biocytogen and Acepodia to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

January 15, 2025

Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform

January 15, 2025

Astraveus Announces World First End-to-End Production of CAR-T Cells Using Microfluidic Technology

January 15, 2025

NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products

January 15, 2025

Asher Bio Announces Clinical Trial Collaboration & Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in SCLC Patients

January 15, 2025

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration:  Established first-in-class cell-free capabilities at commercial scale

January 15, 2025

GSK enters agreement to acquire IDRx, Inc.

January 15, 2025
Page1 … Page3 Page4 Page5 Page6 Page7 … Page27

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.